A recent report has found CD8 T cell hyperfunction in a mouse model of MASH, associating it with reduced tumour surveillance and poor response to immunotherapy for HCC [61]. The gene discussed is CD8A; the disease is metabolic dysfunction-associated steatohepatitis.